How this Peninsula company is turning lung drug royalties into acquisitions


With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.

Previous Wells Fargo taps its representation, inclusion exec as new CEO of consumer lending
Next Dangerously Delicious Pies closes store in Annapolis